Turkmenistan led the ranking of countries in the Commonwealth of Independent States (CIS) by number of COVID-19 vaccination doses administered per 100 population, at over 210 as of September 4, 2022. Uzbekistan ranked second, with about 204 total vaccinations per 100 people. In Russia, nearly 54 people per 100 residents were fully vaccinated.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Numerous studies have attempted to identify potential risk-factors associated with COVID-19 infection, including inter alia: age, diet, higher population density, and the quality and availability of health services. The objective of the current study is to analyze the weight of four covariates on a daily infection rate from SARS-COV2 virus. The method used is regression analysis, where each variable is converted to the standard normal distribution function. Results demonstrate that of the four investigated covariates, vaccination and population size have the highest weights. Given the empirical analysis, the most efficient way to achieve a reduction in the spread of the pandemic is via appropriate vaccination programs. Numerous studies have attempted to identify potential risk-factors associated with COVID-19 infection, including inter alia: age, diet, higher population density, and the quality and availability of health services. The contributions of this article are threefold: We use a unique method to test the COVID-19 vaccine effectiveness. We follow the COVID-19 infection growth rate in each of the 171 Israeli municipalities, starting from 11 March 2020 (the first documentation of COVID-19 cases) until 21 September 2021, where COVID-19 vaccinations were available starting from 20 December 2020.A unique feature of Israel is the early initiation of a nationwide vaccination campaign, which resulted in the full vaccination (i.e. receipt of two vaccine doses) in more than half the population by the end of March 2021. Consequently, Israel provides an appropriate case study to examine the efficiency of the vaccination.The conventional empirical model uses different units of measurement of each explanatory variable. Unlike previous studies, we estimate a model with identical units of measurement, namely one standard deviation of each independent variable. This target is achieved by normalizing all the variables in the regression model. We use a unique method to test the COVID-19 vaccine effectiveness. We follow the COVID-19 infection growth rate in each of the 171 Israeli municipalities, starting from 11 March 2020 (the first documentation of COVID-19 cases) until 21 September 2021, where COVID-19 vaccinations were available starting from 20 December 2020. A unique feature of Israel is the early initiation of a nationwide vaccination campaign, which resulted in the full vaccination (i.e. receipt of two vaccine doses) in more than half the population by the end of March 2021. Consequently, Israel provides an appropriate case study to examine the efficiency of the vaccination. The conventional empirical model uses different units of measurement of each explanatory variable. Unlike previous studies, we estimate a model with identical units of measurement, namely one standard deviation of each independent variable. This target is achieved by normalizing all the variables in the regression model. Findings suggest vaccination as the factor providing the highest contribution to projected infection growth rate decrease. They stress the high importance of vaccination, and provide further support of vaccination efforts.

This file contains data on COVID-19 vaccinations as registered in the national vaccination register "COVID vaccination Information and Monitoring System". (CIMS) of the National Institute for Public Health and the Environment (RIVM). Individuals have been asked for permission to share their vaccination data with CIMS for each COVID-19 vaccination. Percentage of people giving consent increases with successive vaccination rounds; in the basic series this was approximately 93%, in the booster 95% and in the repeat shot in the autumn round it was even more than 99%. NB: this is only known for the injections made by the Municipal Health Service (GGD); It is not known to other performers. Unauthorised vaccinations are not registered in CIMS. For a timeline of who was invited/eligible for COVID-19 vaccination from when, see table 9.3.2 in RIVM report 2022-0042 (https://doi.org/10.21945/RIVM-2022-0042)

More information on how to access the data:

https://www.cbs.nl/en-en/our-services/custom-and-microdata/microdata-self-research

Methodology

The National Institute for Public Health and the Environment (RIVM) receives from the various the vaccination programme details of the vaccinations carried out which have been authorised in order to: to be included in the national vaccination register CIMS. GGDGHOR Netherlands selects which Vaccination is passed on to CIMS. Vaccinations with the status ‘cancelled’ or ‘failed’ not passed on to CIMS. Furthermore, vaccinations are not delivered to CIMS if the batch number is missing. If multiple vaccinations are registered for the same client on the same day, a selection has been made to determine which vaccination will be transferred to CIMS. If vaccinations have the same round number, the completeness of the variables is first looked at vaccine name and batch number. If these variables are complete for all registrations, a selection made on the basis of the time of delivery. The vaccination that is the first by the GGD Submitted to CIMS. When there is another vaccination If you have been vaccinated less than a week before the selected vaccination, you will be selected vaccination from the CIMS data filtered and not (anymore) supplied to CIMS.

For performers other than the GGD, all vaccinations are delivered unchanged to CIMS. In CIMS the variable ' rank number' added. If two or more vaccinations have the same vaccination date Only the vaccination that was first provided will be given a ranking number. Most of the performers Give yourself a booster code (BS0x). For a small part of the executors who cannot do this themselves, the booster code in CIMS is assigned based on the date of campaign in progress on the The moment the vaccine was given.

Population

The population of this stock consists of all COVID-19 vaccinations registered in CIMS.

The average for 2022 based on 187 countries was 85 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

The average for 2022 based on 187 countries was 84 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

Pairwise Wilcoxon signed-rank comparisons with German COVID-19 vaccines for significant Friedman test.

Vaccination against COVID-19 is making progress globally, but vaccine doses remain a rare commodity in many parts of the world. New virus variants mean that updated vaccines become available more slowly. Policymakers have defined criteria to regulate who gets priority access to the vaccination, such as age, health complications, or those who hold system-relevant jobs. But how does the public think about vaccine allocation? To explore those preferences, we surveyed respondents in Brazil, Germany, Italy, Poland, and the United States from September to December of 2020 using ranking and forced-choice tasks. We find that public preferences are consistent with expert guidelines prioritizing health care workers and people with medical preconditions. However, the public also considers those signing up early for vaccination and citizens of the country to be more deserving than later-comers and non-citizens. These results hold across measures, countries, and socio-demographic subgroups.

We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine supply, starting in late 2020 through early 2022. Our analysis indicates that the best strategy to reduce severe outcomes would be to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the intermediate vaccine availability assumptions and relatively modest compared to a simple mass vaccination approach under high vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical surrogate measure for actual disease-risk targeting; this approach also outperforms both simple mass distribution and ring vaccination. We find that quantitative effectiveness of a strategy depends on whether effectiveness is assessed after the alpha, delta, or omicron wave. However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions.

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

United Kingdom jumped by 5% of Export of Vaccines for Human Use in 2019, compared to a year earlier.

BackgroundThe rapid development and rollout of COVID-19 vaccines helped reduce the pandemic’s mortality burden. The vaccine rollout, however, has been uneven; it is well known that vaccination rates tend to be lower in lower income countries. Vaccine uptake, however, ultimately depends on the willingness of individuals to get vaccinated. If vaccine confidence is low, then uptake will be low, regardless of country income level. We investigated the impact on country-level COVID-19 vaccination rates of both national income and vaccine hesitancy.MethodsWe estimated a linear regression model of COVID-19 vaccine uptake across 145 countries; this cross-sectional model was estimated at each of four time points: 6, 12, 18, and 24 months after the onset of global vaccine distribution. Vaccine uptake reflects the percentage of the population that had completed their primary vaccination series at the time point. Covariates include per capita GDP, an estimate of the percentage of country residents who strongly disagreed that vaccines are safe, and a variety of control variables. Next, we estimated these models of vaccine uptake by country income (countries below, and above the international median per capita GDP) to examine whether the impact of vaccine hesitancy varies by country income.ResultsWe find that GDP per capita has a pronounced impact on vaccine uptake at 6 months after global rollout. After controlling for other factors, there was a 22 percentage point difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by per capita GDP; this difference grew to 38% by 12 months. The deleterious impact of distrust of vaccine safety on vaccine uptake became apparent by 12 months and then increased over time. At 24 months, there was a 17% difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by distrust. The income stratified models reveal that the deleterious impact of vaccine distrust on vaccine uptake at 12 and 24 months is particularly evident in lower income countries.ConclusionsOur study highlights the important role of both national income and vaccine hesitancy in determining COVID-19 vaccine uptake globally. There is a need to increase the supply and distribution of pandemic vaccines to lower-income countries, and to take measures to improve vaccine confidence in these countries.

Tonga's Percentage of children vaccinated against triple vaccine (DPT) is 99% which is the 1st highest in the world ranking. Transition graphs on Percentage of children vaccinated against triple vaccine (DPT) in Tonga and comparison bar charts (USA vs. China vs. Japan vs. Tonga), (Saint Vincent vs. the Grenadines vs. Seychelles vs. Tonga) are used for easy understanding. Various data can be downloaded and output in csv format for use in EXCEL free of charge.

When it comes to the mistrust in the safety of vaccinations in selected countries worldwide, Hungary ranks the highest in this list. ** percent of consumer in Hungary share this attitude. Following in the second place is Turkey, while South Korea can be found at the bottom of the ranking.Statista Consumer Insights offer you all results of our exclusive Statista surveys, based on more than ********* interviews.

Due to widespread Covid vaccination rates, the global trade in vaccines reached $42.5B, the highest level ever. Belgium topped the country rankings by the value of exports this year, followed by Germany and the U.S. Growing global demand stimulates the rapid expansion of Covid vaccine production facilities in the EU.

Micronesia, Federated States of's Measles vaccination, % of children vaccinated is 78% which is the 157th highest in the world ranking. Transition graphs on Measles vaccination, % of children vaccinated in Micronesia, Federated States of and comparison bar charts (USA vs. China vs. Japan vs. Micronesia, Federated States of), (Kiribati vs. Grenada vs. Micronesia, Federated States of) are used for easy understanding. Various data can be downloaded and output in csv format for use in EXCEL free of charge.

As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

Monaco's Measles vaccination, % of children vaccinated is 88% which is the 121st highest in the world ranking. Transition graphs on Measles vaccination, % of children vaccinated in Monaco and comparison bar charts (USA vs. China vs. Japan vs. Monaco), (Saint Kitts vs. Nevis vs. San Marino vs. Monaco) are used for easy understanding. Various data can be downloaded and output in csv format for use in EXCEL free of charge.

Mauritius's Percentage of children vaccinated against triple vaccine (DPT) is 96% which is the 55th highest in the world ranking. Transition graphs on Percentage of children vaccinated against triple vaccine (DPT) in Mauritius and comparison bar charts (USA vs. China vs. Japan vs. Mauritius), (Timor-Leste vs. Cyprus vs. Mauritius) are used for easy understanding. Various data can be downloaded and output in csv format for use in EXCEL free of charge.